Dr Mark Gaze
Dr Mark Gaze from University College Hospital and Great Ormond Street Hospital for Children, London is leading vital clinical trials for children with neuroblastoma, which is one of the most common childhood cancers.
Dr Gaze is currently running a clinical trial comparing a higher dose of radiotherapy with the standard dose for people with neuroblastoma. It is also looking at using a type of radiotherapy called Intensity Modulated Arc Therapy (IMAT). IMAT allows radiotherapy to be directed more accurately at the cancer, affecting fewer healthy cells.
Doctors think that using IMAT means a higher dose of radiotherapy can be given, so the treatment might be better at killing the cancer cells.
Neuroblastoma can be hard to treat, so finding new ways to tackle it is really important. Dr Gaze’s research could provide more options for treating neuroblastoma, ensuring more children survive the disease.
Read more about the IMAT trial here: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-intensity-modulated-arc-therapy-for-people-with-neuroblastoma-imat#undefined